

# eve

HEALTH GROUP

---

**SMARTER INNOVATION, BETTER DELIVERY**

Advancing pharmaceutical and nutraceutical delivery for better health outcomes

**Spark<sup>+</sup>**

**INVESTOR LUNCH**



**ASX: EVE**

© EVE HEALTH GROUP 2025

# Executive Summary

**Eve Health Overview:** An emerging pharmaceutical company with patent-pending, fast-acting drug delivery technology poised to disrupt the underserved women's health market, with a strong pipeline including men's health solutions.



## Two Innovative Products

**Dyspro™** – Fast-acting, non-hormonal gummy for menstrual pain, dysmenorrhoea and endometriosis.

**Libbo™** – Discreet, rapid-onset oral strip for erectile dysfunction.



**Massive, Underserved Markets:** Targeting the US\$10.92B<sup>1</sup> dysmenorrhoea and US\$5.31B<sup>2</sup> erectile dysfunction global markets.



**Patent-Pending Technology:** A nano-emulsion platform that improves the speed and effectiveness of high demand formulations.



**Immediate Commercialisation:** First sales of Dyspro™ launched in Australia in September. Libbo™ expected to launch in Australia in December.

# Market Opportunity: Dysmenorrhoea and Endometriosis

Addressing a significant need in the women's health market for pain relief. Existing treatments for menstrual pain and endometriosis often have **slow onset**, rely on **hormonal therapies**, and **undesirable side effects**.



Up to

**90%**

of Australian women and adolescent girls experience dysmenorrhoea. <sup>1</sup>

**1 in 7**

of women Australian women are affected by endometriosis. <sup>2</sup>



Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen (Advil) and naproxen (Aleve) are commonly used for immediate pain relief

**30 – 60 min**

Response time for pain relief. <sup>3</sup>

Up to **35%**

Patients perceived NSAIDs as ineffective. <sup>3</sup>

Up to **39%**

Patients perceived combined oral contraceptive pills as ineffective. <sup>3</sup>



**USD 7.8b**

Market Size in 2024. <sup>4</sup>

**USD 18.5b**

Market Size Projection in 2034. <sup>4</sup>



Up to **20%**

Of adolescent Australian girls experience severe dysmenorrhoea that led to missing school. <sup>5</sup>



**70%**

Of Australian women who experience endometriosis had to take unpaid time off work to manage symptoms. <sup>6</sup>

# Dyspro

## The menstrual pain solution

Dyspro™ is positioned to **set a new standard of care** in the underserved dysmenorrhoea and endometriosis market.

**Addressable Market:** Global market size of US\$10.9b<sup>1</sup> in 2024

**Proprietary Solubility Technology:** Eve's formulation is designed to enhance solubility and support rapid absorption through a proprietary nanoemulsion-based delivery platform<sup>3</sup>.

**Eve Health Formulation:** Menstrual pain relief with reduced potential for adverse effects and improved bioavailability for prompt pain relief.

**Convenient Format:** An easy-to-take gummy.

PRODUCT	TIME TO EFFECTIVENESS
<b>Dyspro™</b>	<b>5 - 15 minutes<sup>2</sup></b>
<b>NSAID</b> (E.g. Ibuprofen, Naproxen)	30 – 60 minutes
<b>Hormonal Contraceptives</b> (E.g. Birth Control Pills, IUDs)	Several days to weeks


## KEY TARGETS

### Non-Hormonal

Naturally-derived products

### Fast Acting

Specifically formulated for improved uptake



### Reduced Adverse Effects

No hormones, no NSAIDs

<sup>1</sup> IMARC Group, Dysmenorrhea Market Outlook 2025-2035 - [www.imarcgroup.com/dysmenorrhea-market-outlook](https://www.imarcgroup.com/dysmenorrhea-market-outlook)

<sup>2</sup> Target onset and bioavailability are based on known properties of active compounds and preliminary formulation design. Further clinical validation is required. Data shown for comparator products is based on published average ranges.

<sup>3</sup> Note: Bioavailability and performance outcomes are subject to confirmation via clinical evaluation. Provisional Patent Application No. 2024902673 outlines nanoemulsion delivery for transmucosal absorption. Preliminary user outcomes suggest favourable onset profile; clinical validation is pending.

# Market Opportunity: Erectile Dysfunction

Addressing a significant need in the men's health market where current treatments are effective, however have **slow onset**, leading to **high dropout rates**.



**40%**

of men at age 40. <sup>1</sup>

**70%**

of men at age 70. <sup>1</sup>



Phosphodiesterase 5 inhibitors (PDE5Is) are the first-line ED therapy. PDE5Is: Viagra, Cialis, Levitra

**60% -70%**

Patients report a positive outcome. <sup>2</sup>

Up to **60 min**

Response time for PDE5Is. <sup>2</sup>

**50%**

Patients stop purchasing PDE5Is. <sup>2</sup>



**USD 5.3b**

Market Size 2025. <sup>3</sup>

**7.6%**

CAGR from 2025 – 2032. <sup>3</sup>



**322m**

Men globally are projected to be affected by erectile dysfunction in 2025. <sup>4</sup>



**3m**

Australian men are estimated to be impacted by erectile dysfunction. <sup>4</sup>



## The erectile dysfunction solution

Libbo™ is positioned to **transform patient experience** in erectile dysfunction with a fast, discreet, and effective solution.

**A revolutionary, fast-acting oral strip for Erectile Dysfunction.**

**Speed:** Targeted effectiveness in 5-15 minutes, compared to 30-60 minutes for competitors.

**Effectiveness:** Targeting 100% effectiveness with a solubilised Vardenafil formulation.

**Convenient Format:** A discreet and easy-to-use oral breath-freshening strip.

### PRODUCT

### TIME TO EFFECTIVENESS

**Libbo™**

(Vardenafil)

**5 – 15 minutes<sup>1</sup>**

**Viagra**

(Sildenafil)

30 – 60 minutes

**Cialis**

(Tadalafil)

30 – 60 minutes

**Levitra**

(Vardenafil)

25 – 60 minutes

### KEY TARGETS

**100%<sup>1</sup>**

Effectiveness from  
60% - 70% with Libbo<sup>1</sup>

**< 10 min**

Time to effect from  
+/- 60 min with Libbo



#### Increased Compliance

Easy to use, discreet formulation,  
increases compliance.

<sup>1</sup> Based on formulation design, known compound properties, and a 10-person observational study, where all participants responded within 15 minutes to a 10mg Libbo oral film. Comparator data from published averages. Clinical validation pending.

<sup>2</sup> Preliminary claims supported by Provisional Patent Application No. 2024902673 (IP Australia), describing a nanoemulsion-based transmucosal delivery platform intended to improve solubility and absorption. Clinical validation pending.

# Product Timeline

Eve Health Group is moving from development to commercialisation, with **Dyspro™** launched in **September 2025** and **Libbo™** expected to launch in **December 2025**.

## Dyspro

**Fast-acting, non-hormonal relief for menstrual pain and endometriosis**

Australian SAS-B launched via Telehealth in September 2025.

**Current** – SAS-B prescribing footprint with future expansion across Australia.

**Q2 2026** – TGA Export-Only approval targeted.

**Q3 2026** – First offshore distribution agreements.

**Q4 2026** – Full TGA ARTG listing submission.

## LIBBO

**Rapid-delivery oral strip, redefining erectile dysfunction treatment.**

Australian SAS-B launch via Telehealth in December 2025.

**Q4 2025** – SAS-B prescribing footprint with future expansion across Australia.

**Q2 2026** – TGA Export-Only approval targeted.

**Q3 2026** – First offshore distribution agreements with MENA markets a primary target.

**Q4 2026** – Full TGA ARTG listing submission.

# Proprietary Technology


Our proprietary nano-emulsion system delivers improved bioavailability, faster onset, targeted delivery, and improved stability for greater efficacy.

- ✓ **Enhanced Solubility:** Improves the solubility of existing, proven drug formulations.
- ✓ **Improved Bioavailability:** Allows for faster absorption and onset of action.
- ✓ **Patent Pending:** Our technology is protected by a provisional patent application, creating a strong barrier to entry.
- ✓ **Versatile:** Can be applied to a range of different products and medical applications.

# The Patent Cliff

## PHARMA PATENT CLIFF

Which drugs will lose exclusivity in the coming years?



## Future EVE Drug Reformulation Targets

Name	Sale	Expiry
Eliquis (Apixaban)	\$12.2B	2026
Biktarvy (Bictegravir)	\$11.9B	2033
Xarelto (Rivaroxaban)	\$6.8B	2025
Xtandi (Enzalutamide)	\$6.3B	2027
Farxiga (Dapagliflozin)	\$6.0B	2025
Imbruvica (Ibrutinib)	\$4.9B	2027
<b>Total Market Value</b>	<b>\$48.1B</b>	

Source: Dr Joanna Sadowska (PhD)

# Key Milestones & News Flow, Reduced Risk Approach

From acquisition, formulation to product launches and export approvals, Eve Health Group is set to deliver a steady cadence of value-driving milestones.

## Key Achievements

**June 25** 100% acquisition of new technology.

**July 25** Partnership with TeleDocs.  
Regulatory pathways cleared for Australia.

**Aug 25** Finalisation of formulation and production of Dyspro™.  
Finalisation of formulation and production of Libbo™.

**Sep 25** Scientific Advisory Board established, Dr Fiona Cousins appointed.  
Initial product launch of Dyspro™.

**Oct 25** Launch of women's health online platform.  
Appointment of Medical Science Liaison to support product awareness with prescribers and pharmacies.

**Nov 25** Telehealth Services Agreement with hubMed.

## Upcoming Milestones

**Q4 2025** Product launch and distribution for Libbo™.  
Further appointments to the Scientific Advisory Board.  
Launch of men's health online platform.

**Q1 2026** Secure extended network of Teleclinics and prescribers.  
Product research and development to accelerate new product pipeline in anticipation of significant products coming off patent.

**Q2 2026** ARTG Export Registration for Dyspro™ and Libbo™.  
Secure offshore distribution partners.

# Corporate Snapshot

## Snapshot

<b>ASX Ticker</b>	EVE
<b>Share Price</b> (14 Nov 2025)	A\$0.028
<b>Shares on Issue</b>	284m (83.33m escrowed until 12 June 2026)
<b>Options on Issue</b>	Nil (23m placement options to be issued)
<b>Market Capitalisation</b> (23 Sept 2025)	A\$8.0m
<b>Cash</b> (Pro-Forma 30 Sept 2025)	A\$1.4m
<b>Enterprise Value</b>	A\$6.7m
<b>Debt</b> (30 Sept 2025)	A\$0.1m


## Board

Board	Role
<b>Rodney Hannington</b>	Non-Executive Chairman
<b>Dr Stuart Gunzburg</b>	Executive Director & Chief Scientific Officer
<b>Bill Fry</b>	Non-Executive Director

## Management

Management	Role
<b>Damian Wood</b>	Chief Executive Officer
<b>Ben Rohr</b>	Chief Operating Officer
<b>Steven Jackson</b>	Chief Financial Officer & Company Secretary

## Ownership



- Nexttract Vendors (Excl B&M)
- Everhoney Biotech Australia P/L
- Hong Kong Junsheng Bolang Technology Co Ltd
- Other Holders
- Balance of Top 50
- Board & Management

# Important Notice and Disclaimer

This presentation has been prepared by and issued by Eve Health Group Limited, to assist it in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation.

You should not act or refrain from acting in reliance on this presentation material. This overview of Eve Health Group Limited does not purport to be all inclusive or to contain all information that its recipients may require in order to make an informed assessment of the Company's prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation and making any investment decision.

Eve Health Group Limited has not verified the accuracy or completeness of the information, statements and opinions contained in this presentation. Accordingly, to the maximum extent permitted by law, the Company makes no representation and give no assurance, guarantee or warranty, express or implied, as to, and takes no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

This presentation contains forward-looking statements regarding the Company's intentions and future business, including the future business of its subsidiaries. These statements reflect current information, expectations, intentions and strategies regarding the future, and are subject to certain risks and uncertainties. Should one or more of these risks or uncertainties materialise, or should any of the underlying assumptions prove incorrect, actual results may vary from the expectations, intentions and strategies described in this presentation. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Other than where required by law, the Company is under no obligation to revise any forward-looking statement to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

All product-related statements in this presentation reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending, and outcomes are subject to change. Investors should not rely on forward-looking statements as guarantees of future performance.

Authorised for release by Stuart Gunzburg, Executive Director.

# References

## **Page 3, Market Opportunity: Dysmenorrhoea and Endometriosis**

- 1 Prevalence and severity of dysmenorrhoea, and management options reported by young Australian women, Australian Family Physician, November 2016
- 2 1 in 7 Australian women aged 44–49 have endometriosis, Australian Institute of Health and Welfare media releases, September 2023
- 3 Perceived Ineffectiveness of Pharmacological Treatments for Dysmenorrhea, Chen X Chen, Janet S Carpenter, Michelle LaPradd, Susan Ofner, J Dennis Fortenberry, September 2021
- 4 Dysmenorrhea Market Size to Reach USD 20.0 Billion by 2035, Impelled by Advancements in Pain Management & Pharmaceuticals, March 2025
- 5 Menstrual pain in Australian adolescent girls and its impact on regular activities: a population-based cohort analysis based on Longitudinal Study of Australian Children survey data, Lauren Cameron, Antonina Mikocka-Walus, Emma Sciberras, Marilla Druitt, Katherine Stanley and Subhadra Evans, The Medical Journal of Australia, May 2024
- 6 Endometriosis and the workplace: Lessons from Australia's response to COVID-19, Mike Armour, Donna Ciccio, Chelsea Stoikos, Jon Wardle ANZ Obstetrics & Gynaecology Journal, November 2021

## **Page 5, Market Opportunity: Erectile Dysfunction**

- 1 Feldman et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151:54–61, January 1994
- 2 Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation," Journal of Sexual Medicine, May 2012.
- 3 Coherent Market Insights - <https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200>
- 4 Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023



1/245 Churchill Ave, Subiaco WA 6008

+61 8 6465 5500

[info@evehealthgroup.com.au](mailto:info@evehealthgroup.com.au)

[WWW.EVEHEALTHGROUP.COM.AU](http://WWW.EVEHEALTHGROUP.COM.AU)

SMARTER INNOVATION, BETTER DELIVERY